Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.

Chrysant SG.

Curr Hypertens Rep. 2013 Oct;15(5):475-83. doi: 10.1007/s11906-013-0377-9. Review.

PMID:
23917809
[PubMed - indexed for MEDLINE]
2.

The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.

Chrysant SG, Chrysant GS.

J Clin Hypertens (Greenwich). 2012 Sep;14(9):644-9. doi: 10.1111/j.1751-7176.2012.00669.x. Epub 2012 Jun 7. Review.

PMID:
22947364
[PubMed - indexed for MEDLINE]
3.

Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.

Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH.

Cardiol Rev. 2007 Mar-Apr;15(2):76-86. Review.

PMID:
17303994
[PubMed - indexed for MEDLINE]
4.

[Sex, erectile dysfunction, and the heart: a growing problem].

Görge G, Flüchter S, Kirstein M, Kunz T.

Herz. 2003 Jun;28(4):284-90. Review. German.

PMID:
12825143
[PubMed - indexed for MEDLINE]
5.

[Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].

Liu Y.

Zhonghua Nan Ke Xue. 2013 Dec;19(12):1147-51. Chinese.

PMID:
24432631
[PubMed - in process]
6.

The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.

Kapur V, Chien CV, Fuess JE, Schwarz ER.

Rev Cardiovasc Med. 2008 Summer;9(3):187-95. Review.

PMID:
18953278
[PubMed - indexed for MEDLINE]
7.

PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.

Rosen RC, McKenna KE.

Annu Rev Sex Res. 2002;13:36-88. Review.

PMID:
12836729
[PubMed - indexed for MEDLINE]
8.

Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.

Pomara G, Morelli G, Pomara S, Taddei S, Ghiadoni L, Dinelli N, Travaglini F, Dicuio M, Mondaini N, Salvetti A, Selli C.

J Androl. 2004 Jul-Aug;25(4):625-9.

PMID:
15223851
[PubMed - indexed for MEDLINE]
9.

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O.

Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19. Review.

PMID:
19768639
[PubMed - indexed for MEDLINE]
10.

Novel phosphodiesterase-5 inhibitors: current indications and future directions.

Sharma R.

Indian J Med Sci. 2007 Dec;61(12):667-79. Review.

PMID:
18174638
[PubMed - indexed for MEDLINE]
Free Article
11.

Tadalafil for the treatment of pulmonary arterial hypertension.

Klinger JR.

Expert Rev Respir Med. 2011 Jun;5(3):315-28. doi: 10.1586/ers.11.38. Review.

PMID:
21702653
[PubMed - indexed for MEDLINE]
12.

Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.

Arif SA, Poon H.

Clin Ther. 2011 Aug;33(8):993-1004. doi: 10.1016/j.clinthera.2011.06.008. Epub 2011 Jul 16. Review.

PMID:
21762988
[PubMed - indexed for MEDLINE]
13.

Sexual function in hypertensive patients receiving treatment.

Reffelmann T, Kloner RA.

Vasc Health Risk Manag. 2006;2(4):447-55. Review.

PMID:
17323599
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Cardiovascular effects of phosphodiesterase 5 inhibitors.

Reffelmann T, Kloner RA.

Curr Pharm Des. 2006;12(27):3485-94. Review.

PMID:
17017941
[PubMed - indexed for MEDLINE]
15.

Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions.

Schwartz BG, Jackson G, Stecher VJ, Campoli-Richards DM, Kloner RA.

Am J Med. 2013 Mar;126(3):192-9. doi: 10.1016/j.amjmed.2012.08.015. Review.

PMID:
23410557
[PubMed - indexed for MEDLINE]
16.

[Cardiovascular complications of phosphodiesterase-5 inhibitors].

Dworzański W, Jaskólska A, Szumiło M, Switalska A, Burdan F.

Pol Merkur Lekarski. 2011 Feb;30(176):139-42. Review. Polish.

PMID:
21544985
[PubMed - indexed for MEDLINE]
17.

New treatment options for erectile dysfunction in patients with diabetes mellitus.

Basu A, Ryder RE.

Drugs. 2004;64(23):2667-88. Review.

PMID:
15537369
[PubMed - indexed for MEDLINE]
18.

Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.

Kukreja RC, Salloum FN, Das A, Koka S, Ockaili RA, Xi L.

Exp Clin Cardiol. 2011 Winter;16(4):e30-5.

PMID:
22131856
[PubMed]
Free PMC Article
19.

Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.

Webb DJ, Freestone S, Allen MJ, Muirhead GJ.

Am J Cardiol. 1999 Mar 4;83(5A):21C-28C.

PMID:
10078539
[PubMed - indexed for MEDLINE]
20.

The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.

Schwarz ER, Kapur V, Rodriguez J, Rastogi S, Rosanio S.

Int J Impot Res. 2007 Mar-Apr;19(2):139-48. Epub 2006 Jun 8. Review.

PMID:
16761012
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk